via reuters.com
Activist investor Carl Icahn lashed out at the board of Amylin Pharmaceuticals Inc on Wednesday, urging it to put the company up for sale and threatening a proxy fight.
Icahn, the company's third-largest shareholder with an 8.9 percent stake, criticized Amylin for failing to confirm or deny media reports that it had rejected a takeover offer from Bristol-Myers Squibb Co of $22 a share, or $3.5 billion. Bristol has also declined to comment on the reports.
No comments:
Post a Comment